Not yet recruitingNCT07046663
Long-term Assessment of Chlormethine Gel in Mycosis Fungoides
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Silvia Alberti ViolettiUOC Dermatologia - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
- Enrollment
- 190 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (20)
- AOU Ospedali Riuniti - Clinica di Ematologia, Ancona, Italy
- SC Dermatologia, ASST-Papa Giovanni XXIII,, Bergamo, Italy
- UO Dermatologia - IRCCS Policlinico S.Orsola-Malpighi, Bologna, Italy
- UO Dermatologia ASST Spedali Civili Brescia, Brescia, Italy
- UOC di Dermatologia - Azienda Ospedaliero-Universitaria di Cagliari, presidio Ospedaliero S. Giovanni di Dio, Cagliari, Italy
- UOC Dermatologia - Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", Catania, Italy
- UOC Ematologia - ARNAS Nuovo Ospedale Garibaldi Nesima, Catania, Italy
- S.C. Dermatologia, AUSL Toscana Centro e Università degli Studi di Firenze, Presidio Ospedaliero Palagi, Florence, Italy
- SC Dermatologia, Ente Ospedaliero Ospedali Galliera di Genova, Genova, Italy
- UO Dermatologia, ASST-Lecco, Azienda Ospedaliera A. Manzoni, Lecco, Italy
- UO Dermatologia Clinica - IRCCS Ospedale San Raffaele di Milano, Milan, Italy
- UOC Dermatologia - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- UOC Clinica Dermatologica - AOU "Luigi Vanvitelli", Naples, Italy
- SCDU Dermatologia; AOU Maggiore della Carità di Novara, Novara, Italy
- SC Dermatologia - Fondazione IRCCS Policlinico San Matteo Clinica Dermatologica, Pavia, Italy
- +5 more locations on ClinicalTrials.gov
Collaborators
RECORDATI GROUP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07046663 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07022964CD5 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
See all trials for Aggressive primary cutaneous T-cell lymphoma →